Document Detail

Metastatic castration-resistant prostate cancer: integrating new learnings to optimise treatment outcomes.
MedLine Citation:
PMID:  23872628     Owner:  NLM     Status:  In-Data-Review    
The approval or clinical evaluation of several new agents - cabazitaxel, abiraterone acetate, enzalutamide, sipuleucel-T, and radium-223 - has changed the management of patients with metastatic castration-resistant prostate cancer (mCRPC) prior to or after docetaxel-based chemotherapy significantly. All of these agents have resulted in a significant survival benefit as compared to their control group. However, treatment responses might differ depending on the associated comorbidities and the extent and the biological aggressiveness of the disease. Furthermore, treatment associated side effects differ between the various drugs. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. It is the aim of the current article to: (1) summarize the data of established treatment options in mCRPC; (2) highlight new developments of medical treatment; (3) provide clinically useful algorithms for the daily routine and to (4) point out future developments of medical treatment.
A Heidenreich; D Porres; C Piper; A K Thissen; D Pfister
Related Documents :
3969898 - Aspirin or dipyridamole individually prevent lipid accumulation in primate vein bypass ...
9354198 - Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed as...
23235958 - A prodrug nanoassembly entrapping drugs as a tumor-targeted delivery system.
24642908 - Hyaluronic acid conjugates as vectors for the active targeting of drugs, genes and nano...
22508028 - Patient-derived tumour xenografts as models for oncology drug development.
11401058 - Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first li...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Minerva urologica e nefrologica = The Italian journal of urology and nephrology     Volume:  65     ISSN:  0393-2249     ISO Abbreviation:  Minerva Urol Nefrol     Publication Date:  2013 Sep 
Date Detail:
Created Date:  2013-07-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8503649     Medline TA:  Minerva Urol Nefrol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  171-87     Citation Subset:  IM    
Department of Urology, RWTH University, Aachen, Germany -
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A comparison of the robotic-assisted versus retropubic radical prostatectomy.
Next Document:  Safety and efficacy of photoselective vaporization of prostate in patients receiving anticoagulants ...